Hepatitis C recurrence after liver transplantation

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

End stage liver disease from hepatitis C is the leading indication for liver transplantation (LT) in the United States. Recurrent hepatitis C after LT is universal and causes substantial morbidity and mortality with up to 30% patients developing cirrhosis by the fifth postoperative year. Once cirrhosis is established, the risk of hepatic decompensation is approximately 40% per year. Risk factors associated with accelerated disease recurrence are elevated high viral load prior to transplantation, older donor age, prolonged ischemic time, cytomegalovirus coinfection, intensity of immunosuppression and HIV coinfection. Although the mechanisms of accelerated HCV-induced liver damage after transplantation are poorly understood, strategies employed to limit severe recurrence include avoidance of older donors, early recognition of citomegalovirus, minimization of immunosuppression, particularly T-cell depleting therapies and pulsed steroids for acute cellular rejection. Treatment of recurrent hepatitis C post-transplant is also problematic and fraught with controversy. As there is a paucity of evidence on when treatment should be initiated, out of necessity treatment has been empiric and often varies between centers. As prophylactic treatment immediately after transplantation is rarely effective and associated with numerous side effects, most clinicians acknowledge that treatment should be initiated once early fibrosis has developed although sustained viral rates with pegylated interferon and ribavirin are frequently less than 30%. Side effects are common and can lead to dose reduction or discontinuation of treatment For those patients who develop develop decompensated cirrhosis from recurrent hepatitis C, retransplantation may be considered.

Original languageEnglish
Pages (from-to)235-247
Number of pages13
JournalPanminerva Medica
Volume51
Issue number4
StatePublished - Dec 2009
Externally publishedYes

Fingerprint

Hepatitis C
Liver Transplantation
Recurrence
Fibrosis
Transplantation
Coinfection
Immunosuppression
Therapeutics
Tissue Donors
End Stage Liver Disease
Ribavirin
Liver
Cell- and Tissue-Based Therapy
Viral Load
Cytomegalovirus
Interferons
Steroids
HIV
Morbidity
T-Lymphocytes

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Hepatitis C recurrence after liver transplantation. / Bhat, I.; Mukherjee, Sandeep.

In: Panminerva Medica, Vol. 51, No. 4, 12.2009, p. 235-247.

Research output: Contribution to journalArticle

@article{7d1bc1aab7084b1b9d70471868efa165,
title = "Hepatitis C recurrence after liver transplantation",
abstract = "End stage liver disease from hepatitis C is the leading indication for liver transplantation (LT) in the United States. Recurrent hepatitis C after LT is universal and causes substantial morbidity and mortality with up to 30{\%} patients developing cirrhosis by the fifth postoperative year. Once cirrhosis is established, the risk of hepatic decompensation is approximately 40{\%} per year. Risk factors associated with accelerated disease recurrence are elevated high viral load prior to transplantation, older donor age, prolonged ischemic time, cytomegalovirus coinfection, intensity of immunosuppression and HIV coinfection. Although the mechanisms of accelerated HCV-induced liver damage after transplantation are poorly understood, strategies employed to limit severe recurrence include avoidance of older donors, early recognition of citomegalovirus, minimization of immunosuppression, particularly T-cell depleting therapies and pulsed steroids for acute cellular rejection. Treatment of recurrent hepatitis C post-transplant is also problematic and fraught with controversy. As there is a paucity of evidence on when treatment should be initiated, out of necessity treatment has been empiric and often varies between centers. As prophylactic treatment immediately after transplantation is rarely effective and associated with numerous side effects, most clinicians acknowledge that treatment should be initiated once early fibrosis has developed although sustained viral rates with pegylated interferon and ribavirin are frequently less than 30{\%}. Side effects are common and can lead to dose reduction or discontinuation of treatment For those patients who develop develop decompensated cirrhosis from recurrent hepatitis C, retransplantation may be considered.",
author = "I. Bhat and Sandeep Mukherjee",
year = "2009",
month = "12",
language = "English",
volume = "51",
pages = "235--247",
journal = "Panminerva Medica",
issn = "0031-0808",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "4",

}

TY - JOUR

T1 - Hepatitis C recurrence after liver transplantation

AU - Bhat, I.

AU - Mukherjee, Sandeep

PY - 2009/12

Y1 - 2009/12

N2 - End stage liver disease from hepatitis C is the leading indication for liver transplantation (LT) in the United States. Recurrent hepatitis C after LT is universal and causes substantial morbidity and mortality with up to 30% patients developing cirrhosis by the fifth postoperative year. Once cirrhosis is established, the risk of hepatic decompensation is approximately 40% per year. Risk factors associated with accelerated disease recurrence are elevated high viral load prior to transplantation, older donor age, prolonged ischemic time, cytomegalovirus coinfection, intensity of immunosuppression and HIV coinfection. Although the mechanisms of accelerated HCV-induced liver damage after transplantation are poorly understood, strategies employed to limit severe recurrence include avoidance of older donors, early recognition of citomegalovirus, minimization of immunosuppression, particularly T-cell depleting therapies and pulsed steroids for acute cellular rejection. Treatment of recurrent hepatitis C post-transplant is also problematic and fraught with controversy. As there is a paucity of evidence on when treatment should be initiated, out of necessity treatment has been empiric and often varies between centers. As prophylactic treatment immediately after transplantation is rarely effective and associated with numerous side effects, most clinicians acknowledge that treatment should be initiated once early fibrosis has developed although sustained viral rates with pegylated interferon and ribavirin are frequently less than 30%. Side effects are common and can lead to dose reduction or discontinuation of treatment For those patients who develop develop decompensated cirrhosis from recurrent hepatitis C, retransplantation may be considered.

AB - End stage liver disease from hepatitis C is the leading indication for liver transplantation (LT) in the United States. Recurrent hepatitis C after LT is universal and causes substantial morbidity and mortality with up to 30% patients developing cirrhosis by the fifth postoperative year. Once cirrhosis is established, the risk of hepatic decompensation is approximately 40% per year. Risk factors associated with accelerated disease recurrence are elevated high viral load prior to transplantation, older donor age, prolonged ischemic time, cytomegalovirus coinfection, intensity of immunosuppression and HIV coinfection. Although the mechanisms of accelerated HCV-induced liver damage after transplantation are poorly understood, strategies employed to limit severe recurrence include avoidance of older donors, early recognition of citomegalovirus, minimization of immunosuppression, particularly T-cell depleting therapies and pulsed steroids for acute cellular rejection. Treatment of recurrent hepatitis C post-transplant is also problematic and fraught with controversy. As there is a paucity of evidence on when treatment should be initiated, out of necessity treatment has been empiric and often varies between centers. As prophylactic treatment immediately after transplantation is rarely effective and associated with numerous side effects, most clinicians acknowledge that treatment should be initiated once early fibrosis has developed although sustained viral rates with pegylated interferon and ribavirin are frequently less than 30%. Side effects are common and can lead to dose reduction or discontinuation of treatment For those patients who develop develop decompensated cirrhosis from recurrent hepatitis C, retransplantation may be considered.

UR - http://www.scopus.com/inward/record.url?scp=77952395704&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952395704&partnerID=8YFLogxK

M3 - Article

C2 - 20195234

AN - SCOPUS:77952395704

VL - 51

SP - 235

EP - 247

JO - Panminerva Medica

JF - Panminerva Medica

SN - 0031-0808

IS - 4

ER -